id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-013035-7sfj0czv	Savinelli, Stefano	Reply	2020-09-20		.txt	text/plain	1259	67	41	We read with great interest the article by McCarthy et al., 1 regarding the favourable use of tocilizumab in a series of patients presenting with cytokine storm related to coronavirus disease 2019 (COVID-19) infection. Reducing short-term mortality from cytokine release syndrome may come at the expense of long-term fatality rate, due to secondary healthcare or ventilator-associated bacterial or fungal infections, especially in critically ill patients with increased length of hospitalization in intensive care units (ICU). However, observational studies demonstrate favourable outcomes regarding mortality and risk of proceeding to endotracheal intubation when IL-6RA are used in a pre-critical (pre-intensive care unit (ICU)) setting, such as that described in our report, before the onset of severe respiratory failure. To address these questions, our group has designed a phase 2, open-label, two-stage, multicentre, randomized trial comparing different doses of single-dose administration of tocilizumab in adults with severe, non-critical, COVID-19 with evidence of hyperinflammatory state.	./cache/cord-013035-7sfj0czv.txt	./txt/cord-013035-7sfj0czv.txt